2025
Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067).
Huppert L, Ellisen L, Anders C, Isaacs C, Santa-Maria C, Anampa J, DeMichele A, Balic M, Specht J, Lustberg M, Wolff A, Krop I, Rugo H. Trial in progress: ENCORE—Multicenter prospective registry of sequential antibody drug conjugates (ADCs) in HER2 negative metastatic breast cancer (MBC) (TBCRC-067). Journal Of Clinical Oncology 2025, 43: tps1137-tps1137. DOI: 10.1200/jco.2025.43.16_suppl.tps1137.Peer-Reviewed Original ResearchMetastatic breast cancerReal-world overall survivalProgression free survivalHER2-negative metastatic breast cancerMetastatic triple negative breast cancerStandard of careAntibody-drug conjugatesDisease control rateDuration of responseOverall survivalBreast cancerPatient-reported outcomesFree survivalHER2 negative metastatic breast cancerTreatment strategiesHormone receptor-positive/HER2-negativeNegative metastatic breast cancerTriple negative breast cancerEffective new treatment strategyPhase III clinical trialsRegistry study of patientsKaplan-Meier methodNegative breast cancerIII clinical trialsNew treatment strategies
2021
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, Rimawi MF, Schiff R, Arpino G, De Placido S, Prat A, Generali D. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers 2021, 13: 1458. PMID: 33810205, PMCID: PMC8004645, DOI: 10.3390/cancers13061458.Peer-Reviewed Original ResearchMetastatic breast cancerSingle-agent endocrine therapyNegative metastatic breast cancerEndocrine therapyTarget therapyBreast cancerHormone receptor positive/HER2Phase II/IIIEndocrine-resistant tumorsPIK3CA-mutant tumorsOverall survival benefitValid therapeutic optionInternational treatment guidelinesRisk of relapseLine endocrine therapySystematic literature searchEffective regimenSurvival benefitTreatment guidelinesTherapeutic optionsComparable efficacyPooled resultsClinical trialsClinical subgroupsSensitive disease
2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal Of Clinical Oncology 2020, 38: 4274-4282. PMID: 33119476, DOI: 10.1200/jco.20.02151.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerObjective response rateProgression-free survivalPoly (ADP-ribose) polymerase (PARP) inhibitorsPhase II studyBreast cancerMutation carriersII studyMedian progression-free survivalNegative metastatic breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Clinical benefit rateHER2-negative diseasePlatinum-refractory diseaseGrowth factor receptor 2Population of patientsFactor receptor 2Homologous recombination-related genesConfirmed responsesEligible patientsMeasurable diseaseSecondary endpointsChemotherapy regimensPrimary endpointSGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.
Beckwith H, Medgyesy D, Abraham J, Nanda R, Tkaczuk K, Krop I, Pusztai L, Modi S, Mita M, Specht J, Hurvitz S, Han H, Kalinsky K, Wilks S, O'Shaughnessy J, Hart L, Rugo H, Mitri Z, Garfin P, Burris III H. SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. Journal Of Clinical Oncology 2020, 38: tps1104-tps1104. DOI: 10.1200/jco.2020.38.15_suppl.tps1104.Peer-Reviewed Original ResearchMetastatic breast cancerMonomethyl auristatin EDose-expansion cohortsAntibody-drug conjugatesDose escalationBreast cancerRECIST v1.1Expansion cohortPrior linesCytotoxic chemotherapyMetastatic triple-negative breast cancerGrade 2 peripheral neuropathyInvestigational antibody-drug conjugateNegative metastatic breast cancerLIV-1Triple-negative breast cancerAdequate organ functionHumanized IgG1 monoclonal antibodyKey efficacy endpointsPrimary safety endpointProgression-free survivalDose-limiting toxicityDuration of responseOverall response rateMonths of completion
2011
PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
Olson E, Flores L, Najita J, Curley C, Jeong J, Murray K, Savoie J, Winer E, Krop I. PD05-07: Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer. Cancer Research 2011, 71: pd05-07-pd05-07. DOI: 10.1158/0008-5472.sabcs11-pd05-07.Peer-Reviewed Original ResearchHER2-positive CTCsMetastatic breast cancerHER2-negative metastatic breast cancerNegative metastatic breast cancerHER2-negative CTCsER-positive diseasePositive CTCsBreast cancerDetectable CTCsLobular histologyPositive diseaseNegative CTCsHER2 amplificationProspective validationHER2-Positive Circulating Tumor CellsHER2-negative breast cancerCEP17 ratioTumor cellsInitial screeningMajority of ptsNegative breast cancerHER2/CEP17 ratioCirculating Tumor CellsDuctal histologyBaseline characteristics
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply